Increased Levels of Serum Neural Cell Adhesion Molecule (NCAM) in Patients With Dementia of the Alzheimer Type

TODARO, L. PURICELLI, H. GIOSEFFI, M. G. PALLOTA, E. BAL DE KIER JOFF´E,M. VARELA, AND E. SACERDOTE DE LUSTIG

CELLULAR AND MOLECULAR NEUROBIOLOGY.

Kluwer Academic/Plenum Publishers

Lugar: New York; Año: 2004 vol. 24 p. 178 - 179

0272-4340

NCAM promotes homo and heterophilic binding between neurons, astrocytes and muscle cells and has been implicated in synaptic plasticity, learning andmemory.Ourobjective was to determine whether serum NCAM levels are altered in patients with cognitive deficit as Dementia of the Alzheimer type (DAT). NCAM was measured by Western blot and densitometric quantitative analysis, employing a monoclonal antibody which revealed bands of high (HMW, ¸130 kDa) and low (LMW, <130 kDa) molecular weight. Values were expressed as arbitrary units (AU). 43 DAT patients (Md age: 82 years, range 59–95) and 36 neurological normal subjects matched by age (70 years, 55–87) were studied. It was found that DAT patients presented higher values of all NCAM isoforms respect to controls [LMW: Md 0.70, range 0.56– 18.62AU vs. 0.35, 0.0–1.34, p < 0:01,HMW: 1.18, 0.14–6.24 vs 0.82, 0.0–2.00, p < 0:01]. For both isoforms the value of the percentile 70 of the control population was chosen as cut-off point. On the basis of these values, 55% of DAT patients presented high values of serum LMW and HMW vs only 28% of controls (p < 0:05). On the other side, onlyLMWlevels were associated with the severity of the cognitive impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. the value of the percentile 70 of the control population was chosen as cut-off point. On the basis of these values, 55% of DAT patients presented high values of serum LMW and HMW vs only 28% of controls (p < 0:05). On the other side, onlyLMWlevels were associated with the severity of the cognitive impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. Values were expressed as arbitrary units (AU). 43 DAT patients (Md age: 82 years, range 59–95) and 36 neurological normal subjects matched by age (70 years, 55–87) were studied. It was found that DAT patients presented higher values of all NCAM isoforms respect to controls [LMW: Md 0.70, range 0.56– 18.62AU vs. 0.35, 0.0–1.34, p < 0:01,HMW: 1.18, 0.14–6.24 vs 0.82, 0.0–2.00, p < 0:01]. For both isoforms the value of the percentile 70 of the control population was chosen as cut-off point. On the basis of these values, 55% of DAT patients presented high values of serum LMW and HMW vs only 28% of controls (p < 0:05). On the other side, onlyLMWlevels were associated with the severity of the cognitive impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. the value of the percentile 70 of the control population was chosen as cut-off point. On the basis of these values, 55% of DAT patients presented high values of serum LMW and HMW vs only 28% of controls (p < 0:05). On the other side, onlyLMWlevels were associated with the severity of the cognitive impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. ¸130 kDa) and low (LMW, <130 kDa) molecular weight. Values were expressed as arbitrary units (AU). 43 DAT patients (Md age: 82 years, range 59–95) and 36 neurological normal subjects matched by age (70 years, 55–87) were studied. It was found that DAT patients presented higher values of all NCAM isoforms respect to controls [LMW: Md 0.70, range 0.56– 18.62AU vs. 0.35, 0.0–1.34, p < 0:01,HMW: 1.18, 0.14–6.24 vs 0.82, 0.0–2.00, p < 0:01]. For both isoforms the value of the percentile 70 of the control population was chosen as cut-off point. On the basis of these values, 55% of DAT patients presented high values of serum LMW and HMW vs only 28% of controls (p < 0:05). On the other side, onlyLMWlevels were associated with the severity of the cognitive impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. the value of the percentile 70 of the control population was chosen as cut-off point. On the basis of these values, 55% of DAT patients presented high values of serum LMW and HMW vs only 28% of controls (p < 0:05). On the other side, onlyLMWlevels were associated with the severity of the cognitive impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. p < 0:01,HMW: 1.18, 0.14–6.24 vs 0.82, 0.0–2.00, p < 0:01]. For both isoforms the value of the percentile 70 of the control population was chosen as cut-off point. On the basis of these values, 55% of DAT patients presented high values of serum LMW and HMW vs only 28% of controls (p < 0:05). On the other side, onlyLMWlevels were associated with the severity of the cognitive impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment. p < 0:05). On the other side, onlyLMWlevels were associated with the severity of the cognitive impairment measured by the GDS scale, as 33.3% of DAT with moderate GDS presented high LMW values vs. 55.6% with advanced GDS. In conclusion we observed that patients with neurodegenerative disease of the Alzheimer type presented elevated levels of serum NCAM. AsLMWNCAMseems to be associated with the cognitive impairment, its quantitation may be useful as a marker of the evolution of the disease, helping in the diagnosis and the early treatment.